Direct Oral Anticoagulants Versus Vitamin K Antagonists After Mitral Valve Transcatheter Edge‐to‐Edge Repair in Patients With Atrial Fibrillation: A Single‐Center Observational Study
Journal of the American Heart Association · 2025
DOI: 10.1161/jaha.124.038834 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Jan-Hendrik Schipper und 16 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and University Hospital Cologne, Clinic III for Internal Medicine University of Cologne Germany. Hauptthemen laut MEDLINE: Atrial Fibrillation, Vitamin K, Anticoagulants, Mitral Valve Insufficiency. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Mitral valve transcatheter edge‐to‐edge repair (M‐TEER) has emerged as a viable therapy option in patients with severe mitral regurgitation and high surgical risk. Although atrial fibrillation is common among patients undergoing M‐TEER, the optimal anticoagulatory treatment after the intervention is unknown.
Methods
A single‐center retrospective observational analysis was conducted using data from the M‐TEER registry at the University Hospital Cologne collected from 2019 untill 2021 including patients undergoing M‐TEER between November 2012 and April 2019. Patients with atrial fibrillation receiving consistent anticoagulation following M‐TEER were categorized into a direct oral anticoagulant or a vitamin K antagonist (VKA) group. The primary end point was a composite of ischemic cerebrovascular and bleeding events. Additionally, overall survival was assessed.
Results
Among 613 patients undergoing M‐TEER, 206 met the inclusion criteria, with 61 receiving direct oral anticoagulants and 145 receiving VKAs. After a median follow‐up of 833 (interquartile range, 355–1271) days, the incidence of the composite primary end point did not differ between direct oral anticoagulant and VKA groups (hazard ratio [HR], 0.51 [95% CI, 0.23–1.12]; P =0.07). Similarly, rates of ischemic cerebrovascular events and bleeding events were similar between groups. However, the overall mortality rate was higher in the VKA group (HR, 2.56 [95% CI, 1.54–4.26]; P =0.002). In the multivariable analysis, oral anticoagulation with a VKA was an independent predictor for death (adjusted HR, 2.23 [95% CI, 1.08–5.06]; P =0.03).
Conclusions
Our findings suggest that direct oral anticoagulants may offer comparable efficacy and safety to VKAs in preventing thromboembolic events following M‐TEER in patients with atrial fibrillation. Further randomized trials are needed to confirm these results and establish optimal anticoagulation strategies in this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine and University Hospital Cologne, Clinic III for Internal Medicine University of Cologne Germany.
- Heart Center, Department of Electrophysiology University Hospital Cologne Cologne Germany.
- Center of Cardiology, Cardiology III-Angiology University Medical Center of the Johannes Gutenberg University Mainz Germany.
- Asklepios Klinik St. Georg Hamburg Germany.
- Medical Clinic II University Heart Center Lübeck, University Hospital Schleswig-Holstein Lübeck Germany.
- Asklepios Westklinikum Hamburg Hamburg Germany.
ORCID-Profile: Jan-Hendrik Schipper, Anne-Sophie Sommer, Richard Julius Nies, Clemens Metze, Max Maria Meertens, Jonas Wörmann, Sebastian Dittrich, Jan-Hendrik van den Bruck, Arian Sultan, Jakob Lüker, Daniel Steven, Christopher Hohmann, Roman Pfister, Stephan Baldus, Ingo Eitel, Christian Frerker, Tobias Schmidt
Zitieren
APA
Schipper, J. H., Sommer, A. S., Nies, R. J., Metze, C., Meertens, M. M., Wörmann, J., Dittrich, S., van den Bruck, J. H., Sultan, A., Lüker, J., Steven, D., Hohmann, C., Pfister, R., Baldus, S., Eitel, I., Frerker, C., & Schmidt, T. (2025). Direct Oral Anticoagulants Versus Vitamin K Antagonists After Mitral Valve Transcatheter Edge‐to‐Edge Repair in Patients With Atrial Fibrillation: A Single‐Center Observational Study. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.038834
Vancouver
Schipper JH, Sommer AS, Nies RJ, Metze C, Meertens MM, Wörmann J, et al. Direct Oral Anticoagulants Versus Vitamin K Antagonists After Mitral Valve Transcatheter Edge‐to‐Edge Repair in Patients With Atrial Fibrillation: A Single‐Center Observational Study. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.038834
BibTeX
@article{Schipper2025,
author = {Schipper, Jan-Hendrik and Sommer, Anne-Sophie and Nies, Richard Julius and Metze, Clemens and Meertens, Max Maria and Wörmann, Jonas and Dittrich, Sebastian and van den Bruck, Jan-Hendrik and Sultan, Arian and Lüker, Jakob and Steven, Daniel and Hohmann, Christopher and Pfister, Roman and Baldus, Stephan and Eitel, Ingo and Frerker, Christian and Schmidt, Tobias},
title = {Direct Oral Anticoagulants Versus Vitamin K Antagonists After Mitral Valve Transcatheter Edge‐to‐Edge Repair in Patients With Atrial Fibrillation: A Single‐Center Observational Study},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.124.038834}
}
EUVIMED